Kern Pharma’s chairman and Grupo Indukern CEO, Raúl Díaz-Varela, explains the new strategic direction of the Spanish generics player, how their partnership with Celltrion to commercialise biosimilars has evolved, and analyses the main developments shaping the country’s generics industry, including regulatory changes and pricing policies. In addition, he comments on Kern Pharma’s sponsorship of professional sports and how they help the company improve its products,
The market share of biosimilars in Spain has been increasing but the returns on investment have decreased steadily
